WO1994024870A1 - Retroviral vectors capable of expressing multimeric proteins from multiple translational initiation sites - Google Patents
Retroviral vectors capable of expressing multimeric proteins from multiple translational initiation sites Download PDFInfo
- Publication number
- WO1994024870A1 WO1994024870A1 PCT/US1994/000650 US9400650W WO9424870A1 WO 1994024870 A1 WO1994024870 A1 WO 1994024870A1 US 9400650 W US9400650 W US 9400650W WO 9424870 A1 WO9424870 A1 WO 9424870A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- ires
- sequence
- seq
- retroviral vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/80—Vectors comprising a special translation-regulating system from vertebrates
- C12N2840/85—Vectors comprising a special translation-regulating system from vertebrates mammalian
Definitions
- This invention relates to retroviral vectors that express multiple polypeptide subunits of a eukaryotic protein from a single polycistronic mRNA and the proteins produced from these vectors.
- the expressed proteins are particularly useful for inducing transplantation tolerance.
- Retroviral vectors are useful as agents to mediate gene transfer into eukaryotic cells. These vectors are generally constructed such that the majority of sequences coding for the structural genes of the virus are deleted and replaced by the gene(s) of interest.
- the retroviral vector contains the signals required for packaging of the virus but does not contain the information required for the generation of an infectious virus particle.
- the retroviral vector (in the form of a plasmid DNA) is transfected into a packaging cell line, which is capable of supplying, in trans, the retroviral gene product(s) necessary to generate a virus particle.
- the packaging cell line is incapable of giving rise to a retrovirus in the absence of the retroviral vector.
- Virus produced by the transfected packaging cell line may be used to infect other cells, including retroviral packaging cell lines and hematopoietic cells.
- the retroviral vector sequences may be integrated into the host genome via retroviral mediated integration and the genes of interest contained within the retroviral vector may be stably expressed off the integrated proviral form. It is necessary that the packaging cell lines are generated in such a fashion as to minimize the potential for recombination between the retroviral structural genes and the sequences present in the retroviral vector. If such recombination were to occur infectious retroviral particles might be generated which could replicate in any host cell.
- genes of interest may be incorporated into the proviral backbone in several general ways.
- the most straightforward constructs are ones in which the structural genes of the retrovirus are replaced by a single gene which is then transcribed under the control of the viral regulatory sequences within the long terminal repeat (LTR).
- Other vectors contain promoters in addition to the viral promoter contained in the 5' LTR.
- promoter suppression Emerman & Temin, 1986, Nuc. Acids Res., 14: 9381-9396 . This phenomenon of promoter suppression is the reason that the most recent literature reports in the field have concluded that multiple gene expression from a single transcript is preferred (Adam, M. A. et al., 1991, J. Virol, 65: 4985-4990; Ghattas, I.R. et al., 1991, Mol. Cell. Biol. 11: 5848-5859 and Morgan, R.A. et al., 1992, Nuc. Acids. Re . 20: 1293-1299 ).
- This invention represents the first use of the BiP IRES sequence in a retroviral vector. It also represents the first use of more than two IRESs for translation initiation from a single retroviral transcript, as well as the first use of multiple copies of the same IRES in a single construct. Further, it provides the potential, for the first time, to independently express 4 to 5 polypeptides from a single retroviral construct. The invention further makes possible the production of multiple polypeptides by a single retroviral construct that are capable of forming a single, functional, multimeric protein. A particularly valuable embodiment of this invention provides the first instance of this type of retroviral approach to express heterodimeric major histocompatibility proteins on the cell surface.
- the vectors may be used to express xenogeneic proteins for the specific purpose of inducing transplantation tolerance in potential transplant recipients.
- the retroviral vectors of the invention have been constructed to have several 5' untranslated regions (UTR) derived from either eukaryotic cellular DNA or viral sequences that act as internal ribosome binding sites for multiple translation initiations from a single eukaryotic transcript.
- the 5' untranslated regions preferred in accordance with the invention may be multiple copies of a 210 base pair fragment corresponding to the 5' untranslated region of human immunoglobulin heavy-chain binding protein (BiP) mRNA.
- the vectors may include IRES sequences that are derived from picorna viral sequences as well as the BiP IRES sequence.
- the vectors are capable of producing several polypeptides that, when posttranslationally linked form, functional heteromultimeric proteins.
- the proteins produced with the vectors of the invention are particularly those useful for inducing transplantation tolerance, including several different major histocompatibility complex (MHC) heterodimeric proteins.
- MHC major histocompatibility complex
- LTR retroviral long terminal repeat
- BiP IRES sequence from the human immunoglobulin chain binding protein
- GPT GPT-sequence of the E. coli gpt gene that encodes the enzyme xanthine-guanine phosphoribosyl transferase
- CAT -sequence of the E.
- Transfected GP/E-envAM12 cells are distinguished by the prefix AM, while transfected GP/E-86 cells are distinguished by the prefix GP.
- Transduced PA317 cells with virus generated from GP/E-86 cells are identified by the prefix GPA.
- FIG. 1 graphically illustrates the retroviral vector pL7gCAT and each of vectors pPBM1 through pPBM5, and pPBM7 through pPBM10, each of which is briefly described as follows:
- pL7gCAT This retroviral vector is a derivative of pLNCX(Miller and Rosman, 1989, Biotechniques, 7: 980-990) and is capable of expressing three different genes under the translational control of three BiP IRES.
- This vector also contains two reporter genes which encode chloramphenicol acetyl transferase (CAT) and xanthine-guanine phosphoribosyl transferase (GPT).
- CAT chloramphenicol acetyl transferase
- GPST xanthine-guanine phosphoribosyl transferase
- pPBM1 The 3'LTR of M-MLV present in pL7gCAT has been replaced by the 3'LTR of M-MPSV (murine myeloproliferative sarcoma virus).
- pPBM2 In order to achieve detectable transient expression of the genes from COSM6 cells, a copy of the enhancerless SV40 origin of replication was inserted before the 3'LTR at the ClaI site, thereby generating pPBM2. A unique Bg1II site was created during the construction of pPBM2.
- pPBM2 is designed to express GPT and CAT.
- pPBM3 A copy of the mini-swine MHC class II DR_ cDNA gene (Gustafsson et al. 1990, J.
- pPBM3 is designed to express DR ⁇ , GPT and CAT.
- pPBM4 A polylinker sequence was inserted at the EcoRI site in pPBM3. This modification potentiates the introduction of another gene which would be translated from the 5'LTR. The EcoRI site was destroyed during this modification.
- pPBM4 is designed to express DR ⁇ , GPT and CAT.
- pPBM4-prime The orientation of the SV40 ori fragment was reversed from its orientation in pPBM4.
- pPBM4 The polylinker sequence was eliminated from the vector, the EcoRI site was re-created and one of the ClaI sites was destroyed.
- pPBM5 The neomycin resistance gene was inserted downstream of the second copy of the BiP IRES sequence, between the NotI and BglII sites of pPBM4.
- pPBM5 is designed to express DR ⁇ and the neomycin resistance gene.
- pPBM7 The mini-swine MHC class II DR ⁇ cDNA was inserted after the second BiP IRES sequence in the NotI-Bg1II site of pPBM4.
- pPBM7 was designed to express the mini-swine MHC class II cDNA genes for DR ⁇ and DR ⁇ .
- pPBM8 pPBM7 was modified to include a third BiP IRES sequence and the neomycin resistance gene.
- pPBM7 was designed to expresss the mini-swine MHC class II cDNA genes for DR ⁇ and DR ⁇ , together with the neomycin resistance gene.
- pPBM9 A 2.8 kb fragment was generated by PCR using the primers HindIII-linked 5' DR ⁇ (SEQ. ID. NO: 7) and ClaI-linked-3 'SV40ori ( SEQ. ID. NO: 5), utilizing pPBM8 as template.
- pPBM10 is identical to pPBM9 except that the SV40 ori has been eliminated.
- a 2.62 kb fragment was generated by PCR using primers HindIII-linked 5' DR ⁇ (SEQ. ID. NO: 7) and ClaI-linked 3' Neomycin (SEQ. ID. NO: 19) and pPBM8 as a template. The DNA fragment was inserted into HindIII and ClaI digested pPBM4.
- FIG. 2 shows a schematic diagram of the protocol used to construct pPBM1 from pL7gCAT.
- ClaI-SacI fragment of pL7gCAT was exchanged with that of pMPZen (Johnson et. al., 1989, EMBO J., 8: 441-_448) in order to replace the MoMLV 3'LTR of pL7gCAT with a hybrid 3'LTR that contains the transcriptional promoter enhancer region of Myeloproliferative Sarcoma Virus (M-MPSV).
- J1, J2, J3 and J4 indicate the oligonucleotide primers used in polymerase chain reactions and correspond to SEQ. ID. NO: 1, SEQ. ID. NO: 2, SEQ. ID. NO: 3 and SEQ. ID. NO: 4, respectively.
- Figure 3 shows an autoradiograph of a thin layer chromatographey plate depicting the results of an assay for the activity of the chloramphenicol acetyl transferase (CAT assay).
- CAT assay Rous Sarcoma Viral promoter-driven expression of the CAT gene (pRSVcat - ATCC 37152) is the positive control for demonstrating the conversion of 14 C-labeled chloramphenicol to its acetylated monomeric form. All other vectors are as described in the text.
- Figure 4 shows a bar graph demonstrating the amount of neomycin phospho-transferase polypeptide produced per ml of the COSM6 cell lysates following transient expression of the retroviral construct, pPBM5.
- Neo-pl and Neo-flask refer to experiments demonstrating that pPBM5, containing the neomycin phosphotransferase gene, when transfected into COSM6 cells grown on a tissue culture plate (Neo-pl) or in a tissue culture flask (Neo-flask), respectively, expressed high levels of neomycin phosphotransferase.
- RSV-pl stands for a similar transfection with pRSV-CAT which was used as the negative control.
- Figure 5 shows a flow cytometry analysis detailing the expression of mini-swine MHC class II molecules following transient transfection of COSM6 cells.
- Figure 6 is a flow chart summary for the experiments reported in Example 2.
- Figure 7 shows a flow cytometry analysis of the surface expression of the mini-swine MHC class II DR ⁇ / ⁇ heterodimer from integrated polycistronic retroviral constructs.
- the histograms were obtained by staining with the antibody 40D which specifically recognizes the DR ⁇ / ⁇ heterodimer and with 76-2- 11 antibody which is specific for IgG2b and which is the isotype control for 40D.
- Figure 8 shows a flow cytometry analysis of individual G418 resistant sub-clones obtained after transfection with pPBM8. Is each panel the histogram obtained by staining with 40D antibody was superimposed on that obtained with 76-2-11. The cells were also stained with an MHC Class I antibody, B1094.
- a and C) are the histograms obtained from untransfected GP/E-86 and GP/E-envAM12 cell lines, respectively.
- B is the histogram of the subclone GPl 2 -2 which was derived by transfection of GP/E-86 cells with pPBM8.
- D is the histogram of the subclone Am1 1 a -6 which was derived by transfection of GP/E-envAM12 cells with pPBM8.
- Figure 9 shows a photograph of an agarose gel showing the DNA fragment produced by polymerase chain reaction using a primer specific for the 5' end of porcine DR ⁇ cDNA, HindIII-linked 5' DR ⁇ (SEQ. ID. NO. 7) in conjunction with a primer specific for the 3' end of porcine DRa cDNA, BglII-linked 3'DR ⁇ ( SEQ. ID. NO. 16).
- the template DNAs used for the PCR analysis were obtained from individual retroviral sub-clones, lane 1 is ⁇ -BstEII DNA marker; lane 2 is DFK cells, a negative control (Hirsch, F. et. al., 1992. J. Immunol.
- lane 3 is AM1 1 a -6; lane 4 is AM1 1 a -4; lane 5 is AM1 1 c -3; lane 6 is GP2 3 -1; lane 7 is GP9 1 a -3; and lane 8 is GP1 2 -2.
- Figure 10 shows the Southern blot analysis of the chromosomal DNAs from the transfected G418 resistant producer cell lines which were generated using pPBM8.
- (A) shows an autoradiograph in which the respective names of the transfected cell lines are indicated at the top of each lane.
- the radioactively labeled probe was a randomly primed porcine DR ⁇ cDNA fragment.
- the sizes of the DNA fragments were estimated by comparing the mobilities of the bands to those of ⁇ BstEII DNA markers.
- the estimated size of the DNA fragments in each lane is indicated by the arrow.
- (B) is a schematic representation of the retroviral insert in pPBM8. Sizes of DNA fragments which might have been generated through potential deletional events occurring as a consequence of recombination between the BiP sequences are indicated.
- Figure 11 shows a graphical illustration for each of vectors pPBM13 and pPBM14.
- pPBM13 is designed to express the DR ⁇ sequence under the translational control of the 5'LTR and the DR ⁇ sequence under the translational control of the BiP IRES sequence.
- pPBM14 is identical to pPBM13 except for the inclusion of the neomycin resistance gene which is under the control of the EMCV IRES.
- Figure 12 shows a flow cytometry analysis of the expression of the mini-swine MHC class II DR ⁇ / ⁇ heterodimer on the surface of COSM6 cells transiently transfected with pPBM13.
- the histogram was obtained by staining the cells with antibody 76-2-11 (an isotype control), antibody W362 (specifically recognizes monkey class I) or antibody 40D (specific for MHC class II DR ⁇ / ⁇ heterodimer).
- Figure 13 shows flow cytometry analyses of the expression of the mini-swine MHC class II DR ⁇ / ⁇ heterodimer on the surface of GP/E-86 cells.
- A GP/E-86 cells which had been transfected with pPBM5 which does not contain the sequences enabling DR ⁇ / ⁇ heterodimer expression.
- B -
- D show histograms for individual G418 resistant clones, generated by transfection of GP/E-86 cells with pPBM14.
- Figure 14 shows flow cytometry analyses of sub-clones derived from PA317 cell line transduced with a transiently expressed viral supernatant from GP/E-66 cells, transfected with pPBM14.
- A is a flow cytometry analysis of PA317 cells transduced with the supernatant obtained from mock-transfected GP/E-86 cells.
- B -(F) are flow cytometry analyses for individual transduced G418 resistant sub-clones.
- Figure 15 shows a bar graph detailing the percentage of cells expressing the MHC class II DR ⁇ / ⁇ heterodimer on the surface at any given time, relative to the isotype control.
- the name of each subclone is as indicated on the abscissa of the bar graph.
- Figure 16 shows the results from slot blot hybridization experiment of RNA isolated from the supernatants of G418 resistant sub-clones.
- A Blot hybridized with randomly primed radioactively labeled DR ⁇ probe.
- B Blot hybridized with randomly primed radioactively-labeled DR ⁇ probe. The names of the sub-clones are as indicated.
- the invention provides retroviral vectors comprising (i) a single transcription regulatory sequence at the 5' region thereof; (ii) a first DNA coding sequence; (iii) at least one additional DNA coding sequence; and (iv) an IRES sequence controlling the translation of each such additional DNA coding sequence of (iii), wherein the vector expresses multiple independent polypeptides capable of posttranslational combination to form at least one functional multimeric protein.
- the retroviral vectors produce, for example, a functional heterodimeric protein of the major histocompatibility complex.
- the IRES is a BiP IRES.
- Such vectors where the IRES is a BiP IRES preferably produce a single heterodimeric protein of the major histocompatibility complex.
- Exemplary vectors are selected from the group of pL7gCAT, pPBM1 through pPBM14 and derivatives of any of them ("derivative" refers to structurally modified but substantially functionally equivalent constructs).
- cells containing the retroviral vectors of this aspect which cells are preferably mammalian (particularly human).
- a retroviral vector comprising (i) a single transcription regulatory sequence at the 5' region thereof; (ii) a first DNA coding sequence; (iii) at least two additional DNA coding sequences; and (iv) IRESs controlling the translation of each such additional coding sequence to express at least one functional multimeric protein, wherein at least one of such IRESs is a cellular IRES.
- at least one such cellular IRES is a mammalian IRES (e.g., a BiP IRES) and the other IRESs can be viral IRESs, (e.g., encephalomyocarditis IRES, a polio virus IRES or a hepatitis virus IRES).
- the invention provides a cell or tissue made to contain the retrovirus of the invention.
- the cell is preferably human.
- the invention provides a method for inducing immune tolerance in a human recipient for graft transplantation which comprises reintroducing, into said human recipient, cells explanted from said human and made to contain a vector of the invention.
- the DNA coding sequences code for polypeptides of a functional heterodimeric protein of the major histocompatibility complex of a non-human.
- the non-human is porcine (e.g., miniature swine) or primate.
- the protein product of the vector(s) of the invention is a functional protein formed of multiple polypeptide subunits that are combined by bridging moieties, or "linkers", e.g., disulfide bridges.
- the vectors of the invention are constructed to express both chains of at least one heterodimeric major histocompatibility complex protein.
- a polycistronic retroviral vector has been constructed which utilizes one copy of the 210 base pair 5' untranslated sequences from Human Immunoglobin Heavy Chain Binding Protein (BiP). This expresses three polypeptides from a single transcript, all utilizing the BiP sequence. Also, one more expressible gene can be put under direct control of a 5' LTR and yet another under control of the SV40 promoter-enhancer.
- BiP Human Immunoglobin Heavy Chain Binding Protein
- a polycistronic retroviral vector has been constructed which utilizes one copy of the 210 base pair 5' untranslated sequence from Human Immunoglobin Heavy Chain Binding Protein (BiP) and one copy of the encephalomycarditis IRES.
- a third polypeptide is expressed under the translational control of the retroviral 5' LTR.
- This vector expresses three polypeptides from a single transcript, two of which post-translationally combine to form a multimeric protein of the major histocompatibility complex.
- one more expressible gene can be put under direct control of the SV40 promoter-enhancer.
- the major advantages in using the BiP sequence are (i) its lack of secondary structure; (ii) absence of any internal AUG sequences; (iii) small size for viral packaging purposes; and (iv) most of all the ability to direct translational initiation in from all three positions irrespective of the downstream distance from the 5'LTR.
- An additional novel aspect of this retroviral vector is the use of a hybrid 3' LTR in which the U5 sequence was taken from Murine Proliferative Sarcoma Virus (M-MPSV), and the R and U3 sequences were taken from M-MLV, because it had been shown previously that M-MPSV bears a very strong transcriptional enhancer which drives over-expression in myeloid tissues. (Bowtell, D.D.L. et. al., 1988. J.Virol. 62: 2464-2473) .
- M-MPSV Murine Proliferative Sarcoma Virus
- retroviral vectors which may be used include vectors derived from Moloney Murine Leukemia Virus, Spleen Necrosis virus, Rous Sarcoma Virus and Harvey Sarcoma Virus. Specific vectors which may be constructed in accordance with the present invention are described in the Examples.
- the retroviral vector LNCX described in Miller and Rosman, 1989, Biotechniques, 7: 960-990 was modified by eliminating the neomycin phosphotransferase gene and the CMV promoter and converting it to the polycistronic vector, pL7gCAT.
- Figure 1 the goal was to replace M-MLV 3'LTR from pL7gCAT with the 3'LTR from Murine Myeloproliferative Sarcoma virus (M-MPSV) which bears a relatively strong enhancer-promoter for transcription in cells derived from myeloid tissue.
- M-MPSV Murine Myeloproliferative Sarcoma virus
- This manipulation was done at the 3'LTR region because the 3'LTR is duplicated during the retroviral integration process and thereby functions as the 5'LTR transcriptional enhancer-promoter from the integrated proviral state.
- a PCR fragment (Mullis, K.B. & Faloona, F.A., 1987, Methods Enzymol., 155: 335-350; Saiki, R.K.
- the primer J1 corresponds to nucleotides 2102 through 2119 of M-MPSV (Genbank accession number K01683).
- the primer J2 corresponds to the reverse complement of nucleotides 2693 through 2709 of the M-MPSV sequence.
- the 608 base pair (bp) PCR fragment was digested with restriction endonucleases ClaI and SacI, electrophoresed through an agarose gel; the 551 bp ClaI/SacI DNA fragment was excised and isolated using the Geneclean II DNA purification kit (Bio 101 Inc., La Jolla, CA).
- pL7gCAT was also digested with ClaI and Sad, electrophoresed through an agarose gel.
- the PCR fragment that had been purified with the Geneclean II solution was ligated to ClaI/SacI digested pL7gCAT. The ligation mixture was used to transform E. coli JM109 (ATCC 53323).
- COSM6 cells (a transformed African Green Monkey Kidney cell line) were transfected (Aruffo, A. and Seed, B., 1987, Proc. Natl. Acad. Sci. U.S.A. 84: 8573- 8577) with pPBM1 and pL7gCAT and tested for CAT expression (Gorman et. al., 1982,. Mol. Cell Biol. 2: 1044-1051; Prost. E. and Moore, D., 1986, Gene 45: 107-111 ).
- CAT activity was not detectable from transfections using either of the two plasmids.
- a PCR fragment was generated using ClaI-linked-3 'SV40ori (SEQ. ID. NO: 5) and ClaI-Bg1II-linked-5'SV40ori (SEQ. ID. NO: 6) primers with pCDM8 plasmid DNA (Seed, B., 1987, Nature 329: 840-842) as the template.
- the PCR fragment was cleaved by ClaI and gel purified.
- the ClaI-digested PCR fragment was subcloned in the ClaI site of pPBM1.
- the SV40ori sequence went in the orientation such that the BglII site is located adjacent to the 3'LTR (See Figure 1: pPBM2 ).
- COSM6 cells were transfected with pPBM2 and analyzed for the production of CAT.
- the transient expression of CAT harvested from COSM6 cells transfected with pPBM2 was comparable to the level of CAT produced by cells transfected with the control plasmid pRSVCAT ( Figure 3). These results indicate that the deletion of the 11 nucleotides from pL7gCAT did not result in the lack of apparent expression of the CAT gene in vectors pL7gCAT and pPBM1. Rather, the lack of expression was a consequence of the inability of these vectors to replicate in COSM6 cells.
- pPBM3 The next vector in the series of vectors which would ultimately result in a vector capable of expressing the mini-swine MHC class II DR ⁇ / ⁇ cDNA genes was one which contained the mini-swine MHC class II DR ⁇ cDNA gene.
- the DR ⁇ cDNA-containing plasmid pPBSKSII-DR ⁇ c (Gustafsson, K. et. al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87: 9798-9602; Shafer, G.E. et. al., 1991, Proc. Natl. Acad. Sci. U.S.A.
- a polylinker sequence containing BstXI, SspI and MluI restriction sites was created by annealing two 25 bp long complementary oligonucleotides polyl (SEQ. ID. NO: 9) and poly2 (SEQ. ID. NO: 10) and inserting the fragment into the EcoRI site in pPBM3, thereby generating pPBM4.
- DNA sequence analysis of pPB 4 revealed that three copies of the polylinker were present in the plasmid. For subsequent constructions it was necessary to change the orientation of the SV40 ori such that the BglII site would be located at the 5' end of the SV40 ori fragment.
- the SV40ori fragment was excised and re-subcloned in ClaI digested pPBM4 vector, generating pPBM4-prime.
- pPBM4- prime the polylinker was eliminated,. the EcoRI site was re-created and the ClaI site at the 3' end of SV40ori sequence was destroyed.
- a BiP IRES-containing DNA fragment was generated from pL7gCAT by PCR using the primer NotI-linked 5' primer(SEQ. ID. NO: 11), which contains the nucleotides 376 - 400 of the human GRP78 sequence (Genbank Accession number M19645) and a NotI site, and primer EcIR (SEQ. ID. NO: 12), which contains the reverse complement to nucleotides 569-587 of the human GRP78 sequence (Genbank Accession number M19645) and an EcoRI site.
- the PCR fragment was cleaved with NotI and EcoRI and purified by gel electrophoresis and GeneCleanII.
- a neomycin phosphotransferase resistance gene-containing DNA fragment was generated by PCR using primer EXneo(SEQ. ID. NO: 13), which contains nucleotides 149 - 177 of the neomycin resistance gene (Genbank Accession number J01834)) and sites for EcoRI and XhoI, and primer BglII-linked 3' neomycin (SEQ. ID. NO: 14), which contains the reverse complement to the neomycin resistance gene nucleotides 922 - 945 and a BglII site.
- the plasmid pSV2Neo was used as the template in the PCR reaction.
- the PCR fragment was cleaved with EcoRI and BglII and purified by gel electrophoresis and GeneCleanll .
- the two PCR fragments were directionally inserted in NotI and BglII digested pPBM4-prime, giving rise to pPBM5 ( Figure 1).
- COSM6 were transfected with pPBM5. 48 hr after transfection the cells were harvested and analyzed for the level of neomycin phosphotransferase activity expressed intracellularly using a NPTII ELISA kit #5307-543210 (Five-Prime To Three-Prime, Boulder, CO). The results of the assay are presented in Figure 4.
- pPBM7 pPBM4 prime was used as the vector for subcloning the porcine DR ⁇ gene.
- Porcine MHC class II DR ⁇ gene (Hirsch et al., 1992, J. Immunol. 149, 841-846) was derived using Sail-linked 5' primer(SEQ. ID. NO: 15) and BglII-linked 3' primer(SEQ. ID. NO: 16) using pPBSKSII-DR ⁇ c as template plasmid.
- the BiP sequence was isolated by PCR from pL7gCAT using NotI-linked 5' primer (SEQ. ID. NO: 11) and Sail-linked 3' primer (SEQ. ID. NO: 17).
- the vector was generated by digesting pPBM4 -prime with NotI and BglII.
- the BiP IRES sequence and DR ⁇ sequence were then directionally subcloned in pPBM4 - prime, to give rise to pPBM7.
- pPBM7 contains the sequences for the mini-swine MHC class II cDNA genes for DR ⁇ and DR ⁇ .
- pPBM8 Construction of pPBM8: pPBM7 was digested with BglII and the 5'-termini of the vector were dephosphorylated, using calf intestinal alkaline phosphatase (Promega Corp. Madison, WI). The BiP-Neomycin fragment to be inserted at the BglII site was isolated by PCR using BglII-linked 5' BiP primer (SEQ. ID. NO: 18) and BglII-linked 3' Neomycin primer (SEQ. ID. NO: 14) using pPBM5 as the template. To determine the orientation of the fragment in the sub-clones, DNA from the sub-clones was analyzed by digestion with a combination of several restriction enzymes.
- pPBM8 contains the sequences for the mini-swine MHC class II cDNA genes for DR ⁇ and DR ⁇ together with the G418 resistance gene. Construction of pPBM9: After finishing the construction of pPBM8, it was discovered that the polylinker sequence had been eliminated at the time of constructing pPBM4-prime from pPBM4. Therefore, in order to insert the polylinker sequence into pPBM8, a 2.8 kb PCR fragment was generated using pPBM8 as template and the primers HindIII-linked 5' DR ⁇ (SEQ. ID. NO: 7) and ClaI-linked 3'SV40ori (SEQ. ID. NO: 5).
- pPBM9 contains the sequences for the mini-swine MHC class II cDNA genes for DR ⁇ and DR ⁇ .
- pPBM10 A PCR fragment was generated using primers HindIII-linked 5' DR ⁇ (SEQ. ID. NO: 7) and ClaI-linked 3' Neomycin (SEQ. ID. NO: 19) and pPBM8 as the template. The PCR fragment was cleaved with HindIII and ClaI and purified by gel electrophoresis and GeneCleanll. The fragment was inserted into the vector fragment of NotI and ClaI digested pPBM4., thereby generating pPBM10.
- pPBM10 contains the sequences for the mini-swine MHC class II cDNA genes for DR ⁇ and DR ⁇ but differs from pPBM9 insofar as the SV40ori sequence was eliminated.
- pPBM10 was used for the generation of the retroviral packaging cell lines, designed to express the mini-swine MHC class II DR ⁇ / ⁇ heterodimer.
- COSM6 cells were transiently transfected with (A) pPBM5 or (B) pPBM7. After 48 hr the cells were analyzed for the cell surface expression of the MHC class II DR ⁇ / ⁇ heterodimer.
- the primary antibody used was ISCR3, which specifically recognizes an epitope of the DR ⁇ only when both DR ⁇ and DR ⁇ are presented as a heterodimer on the surface of the cell (Watanabe, M. et al., 1983, Transplantation 36: 712 -718).
- the cells were also stained with the W632 antibody (Pescovitz, M.D. et al., 1984, J. Exp. Med. 160: 1495- 1505) that specifically recognizes monkey MHC Class I protein.
- the primary antibody reaction was followed by incubating the cells with the secondary antibody, fluorescein isothiocyanate (FITC)- conjugated goat anti-mouse immunoglobulin.
- the stained cells were analyzed using a FACScan flow cytometer (Becton Dickinson, San Jose, CA).
- Figure 5 shows the data displayed in a histogram format as cell number (ordinate) vs. logarithm of fluorescence (abscissa). Dead cells were eliminated from the analysis by appropriate gating.
- the pPBM8 retroviral vectors were used to transfect, using a transfection kit (Stratagene, CA), either the ecotropic packaging cell line, GP/E-86 or the amphotropic packaging cell line GP/E- envAM12., both packaging cell lines were obtained from Dr. Arthur Bank (Columbia University). Forty-eight hours after transfection, transiently expressed virus in the supernatant was recovered by filtration through a low protein binding syringe filter and added to a 20% to 30% confluent plate of recipient cells for transduction in presence of 8 mg/ml Polybrene (Sigma, St Louis, MO).
- GP/E- envAM12 cells were the recipient cells for the supernatant from GP/E-86 cells and vice versa. After 4 hours of infection, the viral supernatant was removed and complete medium was added to allow the cells to undergo 2-3 cycles of replication in 2-3 days. At this point the transduced cells were split in several dilutions and 0.8 mg/ml of active G418-containing medium was added. Under these growth conditions, only the cells expressing the neomycin phosphotransferase gene survived . After 14 days of selection in G41 ⁇ -containing medium, transduced sub-clones were picked and expanded, either as isolated sub-clones or mixtures of sub-clones. Meantime, the transfected cells were also grown in selective medium and subsequently analyzed for DR ⁇ / ⁇ expression.
- Flow cytometry analyses of the transduced cell lines were performed with antibodies such as ISCR3 (Watanabe et al. supra) or 40D (Pierres, M. et al., 1980, Eur. J. Immunol. 10: 950 -957), both of which recognize porcine MHC classII-DR ⁇ polypeptide only when it forms a heterodimer with the DR ⁇ polypeptide.
- Figure 7 shows the data obtained from the mixture of sub-clones, referred to as "bulk”. Neither of the untransfected cell lines exhibit enhanced fluorescence staining with the anti-class II antibody 40D (see Figure 7A and 7B).
- FIG. 8A shows the superimposed histograms of the control (untransfected, G418 sensitive) GP/E-86 cells, obtained by staining with surface antibody 40D for porcine DR ⁇ / ⁇ heterodimer and with the isotype control antibody 76-2-11.
- the histogram obtained by staining cells with the antibody B1094 (Dr. D. H.
- the untransfected cell line GP/E-envAM12 does not express the MHC class II DR ⁇ / ⁇ heterodimer ( Figure 8C), while the transfected cell line AM1 1 a -6 shows a high level of expression of the DR ⁇ / ⁇ heterodimer ( Figure 8D).
- Statistical analyses as obtained by legitimate gating of the fluorescence histograms showed that 42% and 65% of the total cell population express DR ⁇ / ⁇ heterodimer from the ecotropic and amphotropic producer sub-clones respectively.
- the titer of virus stocks produced from both the producer cell lines on NIH-3T3 cells were determined to be about 2 ⁇ 10 5 .
- the cell were lysed by the addition of 400 ⁇ l 2X lysis buffer (2X lysis buffer contains 0.2 M Tris-HCl, pH 7.0, 0.1 M Na 2 EDTA, 2% SDS, 0.1 M NaCl, 400 ⁇ g/ml proteinase K.
- the lysed cells were scraped at room temperature and incubated overnight at 55oC. The solution was then extracted five times with buffer-saturated phenol-chloroform.
- the DNA was ethanol-precipitated and re-dissolved in 10 mM Tris-HCl, pH 7.0 , 1 mM Na2EDTA, 50 ⁇ g/ml DNase-free RNase at 37°C for 1 hour.
- the DNA was re-extracted with phenol-chloroform and ethanol-precipitated.
- the DNA was re-suspended in 10 mM Tris-HCl, pH 7.0, 1 mM Na 2 EDTA.
- For Southern blot analysis the DNA (20 ⁇ g) was digested with Sad which cleaves the retroviral vectors only in the 5' and 3' LTRs.. The digested DNA was electrophoresed through 1% agarose and transferred to a nitrocellulose filter (Scheicher and Schuell, Keene, NH).
- FIG. 10A shows an autoradiograph of Sad digested DNA from the cell lines probed for the presence of sequences hybridizing to the pig DR ⁇ probe.
- the multiplicity of bands corresponding to 4.9 kb, 3.6 kb and 3.0 kb can be interpreted using the schematic diagram in Figure 10B and correspond to the sizes expected if the integrated DNAs had undergone homologous recombination between the copies of the BiP IRES sequences.
- the frequency of the deletion events in the transfected retroviral packaging cell lines can be explained by the ability of the produced virus to super-infect the host cell and subsequent retrovirus-mediated homologous recombination.
- the phenomenon of super-infection has been reported (Muenchau et. al., 1990, Virology 176: 262-265).
- There are several recent reports in the literature regarding the occurrence of retrovirus-mediated homologous recombination Zhang and Temin, 1993, Science, 259: 234-238; Temin, H., 1993, Proc. Natl. Acad. Sci. USA, 90: 6900-6903).
- pPBM7 ( Figure 1) was modified so that the DR ⁇ cDNA gene could be under the direct control of the 5 'LTR for translational initiation.
- the EcoRI-BspEI fragment which contains the 5' cDNA sequence of DR ⁇ from pBSKSII-DR ⁇ plasmid (Gustaffson, K. et al., 1990, Proc. Natl. Acad. Sci. USA, 87: 9798-9802) was used to replace the similar fragment from pPBM7 which contained not only the 5' sequence of DR ⁇ but also the first BiP IRES sequence.
- the new construct, pPBM13, ( Figure 11) thus contains the DR ⁇ gene under the translational control of the 5 'LTR.
- the DR ⁇ cDNA gene remains under the translational control of the BiP IRES.
- pPBM13 does not contain sequences for selection in eukaryotic cells.
- pPBM13 was modified as follows. A DNA fragment containing a second, non- homologous IRES, was generated using the polymerase chain reaction - the plasmid pG1EN (Genetic Therapy Inc. Gaithersburg, MD) was subjected to the polymerase chain reaction in the presence ef primers BglII-XhoI-linked 5' EMC (SEQ. ID. NO: 20) and BglII-linked 3' neomycin (SEQ. ID. NO: 14). The fragment thus amplified contains the 5' untranslated region of the encephalomycarditis virus (EMCV) and the neomycin phosphotransferase gene. The DNA fragment was cleaved with BglII and gel purified before being inserted into the BglII site in pPBM13, thereby generating pPBM14 ( Figure 11).
- EMCV encephalomycarditis virus
- the collected cells were rinsed twice with 1X PBS and 10 6 cells (in 100 ⁇ L) were added to each well of a 96 well micro-titer plate. Appropriately diluted primary antibodies were added to the cells which were stained for 30 min. at room temperature. The non-reactive antibodies were washed off and FITC-conjugated secondary antibody was added for 30 min. at 4°C. After stringent washing of the cells, the cells were analyzed by flow cytommtry. Phosphor-iodide gating (Becton-Dickinson Manual) was used to gate out dead cells.
- Figure 12 shows the results of the flow cytometry analysis, the data is represented in histogram format using the number of cells as the ordinate and the fluorescence intensity as the abscissa. It is apparent from Figure 12 that the vector pPBM13 expresses the mini-swine MHC class II DR ⁇ / ⁇ heterodimer as efficiently as did pPBM7.
- the ecotropic GP/E-86 retroviral packaging cell line was transfected with pPBM14 using the Mammalian Transfection Kit (Stratagene, La Jolla, CA)
- the transiently expressed virus from GP/E-86 cells was harvested 48 hr after transfection, filtered through a low protein binding 0.45 ⁇ M filter (Gelman Sciences, Ann Arbor, MI) and was used to transduce the amphotropic packaging cell line PA317 (ATCC CRL 9078).
- the transduced cells were split in appropriate dilutions and 500 ⁇ g/ml active G418 was added to the medium in order to select G418 resistant cells.
- the transfected GP/E-86 cells were plated in presence of 1 mg/ml active G418 containing media in limited dilutions for scoring the G418 resistant clones.
- Figure 15 displays a bar graph showing the percentage of transduced cells in a particular population which demonstrate a higher level of fluorescence intensity with the antibody recognizing the DR ⁇ / ⁇ heterodimer relative to that recognizing the isotype control.
- RNA was extracted from pelleted virus and an RNA slot blot analysis was performed.
- the autoradiograph in Figure 16 indicates that there are equivalent amounts of DR ⁇ and DR ⁇ RNA for the clones as discerned by the intensity of hybridization with the respective cDNAs as radioactive probes. This argues in favor of the integrity of the proviral genome in the producer sub-clones. Had recombination/deletion occurred we would have expected a difference in the proportionality of the RNA transcripts specific for either DR ⁇ or DR ⁇ because it is likely that viruses bearing two different types of RNA genomes would express different amounts of RNA.
- Virus was harvested from virus producing cells by adding 5 ml of fresh culture media on day 1 to 80% confluent 10 cm dishes for 16 hr. On day 2, the supernatant containing the virus was filtered through 0.45 ⁇ M low protein binding filter and diluted appropriately with media. Then, 0.5 ml of the supernatant from various dilutions was added to 40% confluent dishes of recipient NIH-3T3 (ATCC CRL 1658) cells in presence of 4 ⁇ g/ml of Polybrene. On day 3, fresh media containing 1 mg/ml active G418 was added to the transduced cells and neomycin resistant colonies were scored after 10-12 days by fixing the cells in methanol and staining the cells with Giemsa stain. Virus titer was calculated in colony forming units/ml (cfu/ml) as shown in Table 1.
- the stable G418 resistant NIH-3T3 cells were amplified and tested for presence of replication competent retrovirus (RCR). If any contamination or recombinatorial event was able to give rise to RCR in the amphotropic viral supernatant that was used to infect NIH-3T3 cells, expansion of the NIH-3T3 cells would result in a several-fold amplification of the RCR. By this amplification technique, breakout of a single RCR could be detected by doing marker rescue S+L- assay using PG4 as an indicator cell line (Haapala, D. et al., 1985, J. Virol. 53: 827-833 )or by PCR using primer sequences corresponding to the sequences of envelope protein.
- RCR replication competent retrovirus
- ADDRESSEE Carella, Byrne, Bain,
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6512538A JPH08510636A (en) | 1993-01-20 | 1994-01-17 | Retroviral vector capable of expressing multimeric protein from multiple translation initiation sites |
AU62303/94A AU6230394A (en) | 1993-01-20 | 1994-01-17 | Retroviral vectors capable of expressing multimeric proteins from multiple translational initiation sites |
EP94909464A EP0706319A4 (en) | 1993-01-20 | 1994-01-17 | Retroviral vectors capable of expressing multimeric proteins from multiple translational initiation sites |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US647893A | 1993-01-20 | 1993-01-20 | |
US08/006,478 | 1993-05-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994024870A1 true WO1994024870A1 (en) | 1994-11-10 |
Family
ID=21721102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/000650 WO1994024870A1 (en) | 1993-01-20 | 1994-01-17 | Retroviral vectors capable of expressing multimeric proteins from multiple translational initiation sites |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0706319A4 (en) |
JP (1) | JPH08510636A (en) |
AU (1) | AU6230394A (en) |
CA (1) | CA2162056A1 (en) |
IL (1) | IL108383A0 (en) |
WO (1) | WO1994024870A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0711835A1 (en) * | 1994-11-14 | 1996-05-15 | Immuno Ag | Selection and expression of heterologous proteins using a selection-amplification-system |
DE19514310A1 (en) * | 1995-04-18 | 1996-10-24 | Univ Ludwigs Albert | Vectors for the transfection of eukaryotic cells, their use and thus transfected target cells |
WO1997008330A1 (en) * | 1995-08-23 | 1997-03-06 | Cancer Research Campaign Technology Limited | Expression systems |
WO1997029201A2 (en) * | 1996-02-07 | 1997-08-14 | Max-Delbrück-Centrum für Molekulare Medizin | Retroviral vector for the gene transfer of an il6 antagonist in human haematopoietic stem cells |
WO1998011241A1 (en) * | 1996-09-16 | 1998-03-19 | Merck Patent Gmbh | Oligocistronic expression system for the production of heteromeric proteins |
WO1999024596A1 (en) * | 1997-11-12 | 1999-05-20 | Valentis, Inc. | Expression plasmids for multiepitope nucleic acid-based vaccines |
WO2000053779A1 (en) * | 1999-03-08 | 2000-09-14 | The European Molecular Biology Laboratory | Translation regulation system and methods for use thereof |
WO2002002738A2 (en) * | 2000-07-03 | 2002-01-10 | Gala Design, Inc. | Host cells containing multiple integrating vectors |
WO2002002783A2 (en) * | 2000-07-03 | 2002-01-10 | Gala Design, Inc. | Expression vectors |
WO2002029065A2 (en) * | 2000-10-06 | 2002-04-11 | Oxford Biomedica (Uk) Limited | Retroviral vectors containing internal ribosomal entry sites |
US6436427B1 (en) | 1996-03-22 | 2002-08-20 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
US6852510B2 (en) | 2000-07-03 | 2005-02-08 | Gala Design Inc | Host cells containing multiple integrating vectors |
US7183395B2 (en) * | 2000-01-28 | 2007-02-27 | The Scripps Research Institute | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same |
US7419829B2 (en) | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
US7468275B2 (en) * | 2000-01-28 | 2008-12-23 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
US7560538B2 (en) | 2003-11-05 | 2009-07-14 | University Of Pittsburgh | Porcine isogloboside 3 synthase protein, cDNA, genomic organization, and regulatory region |
US7795493B2 (en) | 2002-08-21 | 2010-09-14 | Revivicor, Inc. | Porcine animals lacking any expression of functional alpha 1, 3 galactosyltransferase |
US8106251B2 (en) | 2002-08-21 | 2012-01-31 | Revivicor, Inc. | Tissue products derived from porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase |
US8222188B2 (en) | 2002-03-28 | 2012-07-17 | Catalent Pharma Solutions, Llc | Antibody libraries |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4036389A (en) * | 1988-07-29 | 1990-03-05 | Zymogenetics Inc. | High efficiency translation of polycistronic messages in eucaryotic cells |
EP0598029B1 (en) * | 1991-08-07 | 2002-02-27 | ANDERSON, W., French | Retroviral vectors containing internal ribosome entry sites |
IL102404A0 (en) * | 1992-07-03 | 1993-01-14 | Daniel Zurr | Method and means for the production of gene products |
-
1994
- 1994-01-17 WO PCT/US1994/000650 patent/WO1994024870A1/en not_active Application Discontinuation
- 1994-01-17 JP JP6512538A patent/JPH08510636A/en active Pending
- 1994-01-17 EP EP94909464A patent/EP0706319A4/en not_active Withdrawn
- 1994-01-17 AU AU62303/94A patent/AU6230394A/en not_active Abandoned
- 1994-01-17 CA CA002162056A patent/CA2162056A1/en not_active Abandoned
- 1994-01-20 IL IL10838394A patent/IL108383A0/en unknown
Non-Patent Citations (5)
Title |
---|
JOURNAL OF VIROLOGY, Vol. 63, No. 4, issued April 1989, S.K. JANG et al., "Initiation of Protein Synthesis by Internal Entry of Ribosomes into the 5' Nontranslated Region of Encephalomyocarditis Virus RNA In Vivo", pages 1651-1660, see Figure 1. * |
JOURNAL OF VIROLOGY, Vol. 65, No. 9, issued September 1991, M.A. ADAM et al., "Internal Initiation of Translation in Retroviral Vectors Carrying Picornavirus 5' Nontranslated Regions", pages 4985-4990, see Figure 1. * |
NATURE, Vol. 353, issued 05 September 1991, D.G. MACEJAK et al., "Internal Initiation of Translation Mediated by the 5' Leader of a Cellular mRNA", pages 90-94, see page 93. * |
NUCLEIC ACIDS RESEARCH, Vol 20, No. 6, issued 1992, R.A. MORGAN et al., "Retroviral Vectors Containing Polycistronic Internal Ribosome Entry Sites: Development of a Putative Gene Transfer System and Applications to Human Gene Therapy", pages 1293-1299, see Figures 5-6. * |
See also references of EP0706319A4 * |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0711835A1 (en) * | 1994-11-14 | 1996-05-15 | Immuno Ag | Selection and expression of heterologous proteins using a selection-amplification-system |
US6114146A (en) * | 1994-11-14 | 2000-09-05 | Baxter Aktiengesellschaft | Expression plasmid, a fusion protein, a transfected eukaryotic cell line, a method of producing foreign proteins, a foreign protein preparation as well as a pharmaceutical composition |
DE19514310A1 (en) * | 1995-04-18 | 1996-10-24 | Univ Ludwigs Albert | Vectors for the transfection of eukaryotic cells, their use and thus transfected target cells |
WO1996033272A1 (en) * | 1995-04-18 | 1996-10-24 | KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITäT FREIBURG | Vectors for the transfection of eucaryotic cells, their use and target cells transfected thereby |
WO1997008330A1 (en) * | 1995-08-23 | 1997-03-06 | Cancer Research Campaign Technology Limited | Expression systems |
WO1997029201A2 (en) * | 1996-02-07 | 1997-08-14 | Max-Delbrück-Centrum für Molekulare Medizin | Retroviral vector for the gene transfer of an il6 antagonist in human haematopoietic stem cells |
WO1997029201A3 (en) * | 1996-02-07 | 1997-10-02 | Max Delbrueck Centrum | Retroviral vector for the gene transfer of an il6 antagonist in human haematopoietic stem cells |
US6436427B1 (en) | 1996-03-22 | 2002-08-20 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
US6649184B2 (en) | 1996-03-22 | 2003-11-18 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
WO1998011241A1 (en) * | 1996-09-16 | 1998-03-19 | Merck Patent Gmbh | Oligocistronic expression system for the production of heteromeric proteins |
WO1999024596A1 (en) * | 1997-11-12 | 1999-05-20 | Valentis, Inc. | Expression plasmids for multiepitope nucleic acid-based vaccines |
WO2000053779A1 (en) * | 1999-03-08 | 2000-09-14 | The European Molecular Biology Laboratory | Translation regulation system and methods for use thereof |
US6610508B1 (en) | 1999-03-08 | 2003-08-26 | Anadys Pharmaceuticals, Inc. | Translation driver system and methods for use thereof |
US7456273B2 (en) | 2000-01-28 | 2008-11-25 | The Scripps Research Institute | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same |
US7183395B2 (en) * | 2000-01-28 | 2007-02-27 | The Scripps Research Institute | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same |
US7468275B2 (en) * | 2000-01-28 | 2008-12-23 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
WO2002002738A2 (en) * | 2000-07-03 | 2002-01-10 | Gala Design, Inc. | Host cells containing multiple integrating vectors |
WO2002002738A3 (en) * | 2000-07-03 | 2002-05-30 | Gala Design Inc | Host cells containing multiple integrating vectors |
WO2002002783A2 (en) * | 2000-07-03 | 2002-01-10 | Gala Design, Inc. | Expression vectors |
US6852510B2 (en) | 2000-07-03 | 2005-02-08 | Gala Design Inc | Host cells containing multiple integrating vectors |
WO2002002783A3 (en) * | 2000-07-03 | 2003-01-16 | Gala Design Inc | Expression vectors |
EP2151493A1 (en) * | 2000-07-03 | 2010-02-10 | Gala Design, Inc. | Host cells containing multiple integrating vectors |
US7378273B2 (en) | 2000-07-03 | 2008-05-27 | Gala Design, Inc. | Expression vectors |
WO2002029065A3 (en) * | 2000-10-06 | 2002-12-27 | Oxford Biomedica Ltd | Retroviral vectors containing internal ribosomal entry sites |
US7419829B2 (en) | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
WO2002029065A2 (en) * | 2000-10-06 | 2002-04-11 | Oxford Biomedica (Uk) Limited | Retroviral vectors containing internal ribosomal entry sites |
US7259015B2 (en) | 2000-10-06 | 2007-08-21 | Oxford Biomedia (Uk) Limited | Vector system |
US8222188B2 (en) | 2002-03-28 | 2012-07-17 | Catalent Pharma Solutions, Llc | Antibody libraries |
US7795493B2 (en) | 2002-08-21 | 2010-09-14 | Revivicor, Inc. | Porcine animals lacking any expression of functional alpha 1, 3 galactosyltransferase |
US8106251B2 (en) | 2002-08-21 | 2012-01-31 | Revivicor, Inc. | Tissue products derived from porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase |
US10130737B2 (en) | 2002-08-21 | 2018-11-20 | Revivicor, Inc. | Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase |
US10912863B2 (en) | 2002-08-21 | 2021-02-09 | Revivicor, Inc. | Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase |
US11172658B2 (en) | 2002-08-21 | 2021-11-16 | Revivicor, Inc. | Porcine animals lacking expression of functional alpha 1, 3 galactosyltransferase |
US7560538B2 (en) | 2003-11-05 | 2009-07-14 | University Of Pittsburgh | Porcine isogloboside 3 synthase protein, cDNA, genomic organization, and regulatory region |
Also Published As
Publication number | Publication date |
---|---|
IL108383A0 (en) | 1994-04-12 |
EP0706319A1 (en) | 1996-04-17 |
AU6230394A (en) | 1994-11-21 |
JPH08510636A (en) | 1996-11-12 |
CA2162056A1 (en) | 1994-11-10 |
EP0706319A4 (en) | 1998-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994024870A1 (en) | Retroviral vectors capable of expressing multimeric proteins from multiple translational initiation sites | |
AU738156B2 (en) | Viral vectors and their uses | |
Hildinger et al. | Design of 5′ untranslated sequences in retroviral vectors developed for medical use | |
JP4409631B2 (en) | Method for producing high-titer virus and efficient retrovirus-mediated transduction into mammalian cells | |
Robbins et al. | Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells | |
JP4733166B2 (en) | Vectors and viral vectors and packaging cell lines for propagating them | |
WO1998012339A9 (en) | Viral vectors and their uses | |
US20020168346A1 (en) | Novel lentiviral packaging cells | |
EP0432216A1 (en) | Recombinant retroviruses with amphotropic and ecotropic host ranges | |
Uckert et al. | Efficient gene transfer into primary human CD8+ T lymphocytes by MuLV-10A1 retrovirus pseudotype | |
AU718551B2 (en) | Vectors comprising SAR elements | |
US20030082559A1 (en) | Methods and reagents for amplification and manipulation of vector and target nucleic acid sequences | |
US5710037A (en) | Retroviral vector particles | |
US6995009B1 (en) | Packaging cell | |
WO1997046687A9 (en) | Vectors comprising sar elements | |
WO1995034639A9 (en) | Novel retroviral envelope and ltr and retroviral vector particles including such envelope and/or ltr | |
Farson et al. | Large‐scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols | |
US20100137415A1 (en) | Vector for gene therapy | |
JP2002542834A (en) | Expression of heterologous genes from IRES transcription cassette in retroviral vector | |
US20180127470A1 (en) | Cell Lines | |
Metz et al. | Harvey Murine Sarcoma Virus/MDR1 Retrovital Vectors: Efficient Virus Production and Foreign Gene Transduction Using MDR1 as a Selectable Marker | |
WO2021070956A1 (en) | siRNA EXPRESSION VECTOR | |
CN115552015A (en) | Engineering immune cells via simultaneous knock-in and gene disruption | |
Mahon et al. | Retrovirus cDNA expression library screening for oncogenes | |
EP4286401A1 (en) | Use of an artificial protein or of a nucleic acid encoding the artificial protein for providing a functional ribonucleoprotein complex |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 1995 424441 Country of ref document: US Date of ref document: 19951027 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2162056 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994909464 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1994909464 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994909464 Country of ref document: EP |